ClinicalTrials.gg
CompletedNCT01590797Updated Aug 17, 2018Results posted

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)

A Phase 3 interventional study of Sitagliptin and Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2018-08-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
467
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
35th of 197
467 · median 102
Started
2012
with 15 others
Phase 3
74 of 198
none open now
Registered
117th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 35th largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 74 in phase 3, and was the 117th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable insulin alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis of this study is that after 24 weeks, the addition of sitagliptin compared with placebo provides greater reduction in hemoglobin A1C (HbA1C) in T2DM participants on insulin alone or in combination with metformin.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • has T2DM
  • is currently on a stable regimen of pre-mixed, intermediate-acting, or long-acting insulin at a dose of at least 12 U/day, either alone or in combination with metformin >=1500 mg/day for ≥ 10 weeks
  • has a Visit 1/Screening between 7.5% and 11.0%
  • is a male, or a female who is highly unlikely to conceive during the study and for 14 days after the last dose of study medication

Exclusion criteria

Exclusion Criteria:

  • has been treated with any antihyperglycemic therapies other than a protocol-required insulin (alone or with metformin) within the prior 12 weeks or has ever

been treated with a dipeptidyl peptidase-4 inhibitor or a glucagon-like peptide-1 mimetic or analogue

  • is currently on treatment with daily use (one or more injections per day) of

pre-prandial short-acting or rapid-acting insulin

  • has a history of 2 or more episodes of hypoglycemia resulting in seizure,

coma, or loss of consciousness, or has had recurrent episodes of hypoglycemia over the past 8 weeks

  • has a history of intolerance or , or has any to sitagliptin, insulin, or metformin
  • is on a weight loss program and not in the maintenance phase, or has started a weight loss medication or has undergone bariatric surgery within 12 months
  • has undergone a surgical procedure within 4 weeks or has planned major surgery during the study
  • has a medical history of active liver disease
  • has had new or worsening signs or symptoms of coronary heart disease within the past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder
  • has a diagnosis of congestive heart failure with Class III - IV cardiac status
  • has a systolic blood pressure ≥ 160 mmHg or a diastolic blood pressure ≥ 90 mmHg
  • has (HIV)
  • has severe peripheral vascular disease
  • is currently being treated for hyperthyroidism or is on thyroid hormone therapy and has not been on a stable dose for at least 6 weeks
  • has a history of ≤ 5 years before the study, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • has a hematological disorder (such as aplastic anemia,

myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

  • is pregnant or breast feeding, or is expecting to conceive or donate eggs during the study, including 14 days after the last dose of study medication
  • is a user of recreational or illicit drugs or has had a recent history of drug abuse
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
467 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.

    Drug: Sitagliptin · Biological: Insulin · Drug: Metformin

  • Placebo comparator
    Placebo

    Participants treated with placebo matching sitagliptin, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.

    Drug: Placebo · Biological: Insulin · Drug: Metformin

Interventions

  • Sitagliptin 100 mg once daily for 24 weeks

    Also known as: Januvia®, MK-0431

  • DrugPlacebo

    Matching placebo once daily for 24 weeks

  • BiologicalInsulin

    Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.

  • At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin

    Time frame: Baseline and Week 24

  2. Number of Participants With One or More Adverse Events

    An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to Week 26

  3. Number of Participants Discontinuing Study Medication Due to an AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to Week 24

Secondary outcomes

  1. Change From Baseline in HbA1C Levels at Week 24 in Participants Receiving Insulin in Combination With Metformin

    Time frame: Baseline and Week 24

  2. Change From Baseline in 2-Hour Post Meal Glucose Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin

    Time frame: Baseline and Week 24

07

Results

Posted Jan 27, 2015

Participant flow

This study was performed with research participants at 28 study centers in China.

Participant flow — Overall Study
MilestoneSitagliptinPlacebo
Started234233
Completed217217
Not completed1716
Withdrew: Adverse event43
Withdrew: Lack of efficacy02
Withdrew: Lost to follow-up01
Withdrew: Protocol violation41
Withdrew: Withdrawal by subject75
Withdrew: Other protocol specified criteria24

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · A1C %
Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin
A1C %SitagliptinPlacebo
Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin-0.67 (-0.79 to -0.55)-0.32 (-0.44 to -0.20)
Statistical analysis
  • Sitagliptin vs Placebo · Robust Regression · p = <0.001 · Mean difference (final values): -0.34 · 95% CI -0.50 to -0.19Robust regression using M-estimation with terms for treatment and the metformin stratum and type of insulin, and baseline A1C (%) as a covariate.
SecondaryChange From Baseline in HbA1C Levels at Week 24 in Participants Receiving Insulin in Combination With Metformin
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · A1C %
Change From Baseline in HbA1C Levels at Week 24 in Participants Receiving Insulin in Combination With Metformin
A1C %SitagliptinPlacebo
Change From Baseline in HbA1C Levels at Week 24 in Participants Receiving Insulin in Combination With Metformin-0.72 (-0.89 to -0.55)-0.34 (-0.51 to -0.17)
Statistical analysis
  • Sitagliptin vs Placebo · Robust Regression · p = 0.002 · Mean difference (final values): -0.38 · 95% CI -0.61 to -0.14Robust regression using M-estimation with terms for treatment and type of insulin, and baseline A1C (%) as a covariate.
SecondaryChange From Baseline in 2-Hour Post Meal Glucose Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-Hour Post Meal Glucose Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin
mg/dLSitagliptinPlacebo
Change From Baseline in 2-Hour Post Meal Glucose Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin-47.9 (-57.0 to -38.8)-21.3 (-30.3 to -12.3)
Statistical analysis
  • Sitagliptin vs Placebo · ANCOVA · p = <0.001 · Mean difference (final values): -26.5 · 95% CI -38.4 to -14.7ANCOVA model with terms for treatment and the metformin stratum and type of insulin, and baseline 2-hr Post- Meal Glucose (mg/dL) as a covariate.
PrimaryNumber of Participants With One or More Adverse Events

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to Week 26
Reported as:
Number · Participants
Number of Participants With One or More Adverse Events
ParticipantsSitagliptinPlacebo
Number of Participants With One or More Adverse Events126116
PrimaryNumber of Participants Discontinuing Study Medication Due to an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to Week 24
Reported as:
Number · Participants
Number of Participants Discontinuing Study Medication Due to an AE
ParticipantsSitagliptinPlacebo
Number of Participants Discontinuing Study Medication Due to an AE42

Adverse events

Collected over Up to Week 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—4/234 (1.7%)83/234 (35.5%)
Placebo—9/233 (3.9%)68/233 (29.2%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventSitagliptinPlacebo
Coronary artery diseaseCardiac disorders0/2341/233
Duodenal ulcer haemorrhageGastrointestinal disorders0/2341/233
Gastric polypsGastrointestinal disorders0/2341/233
Diabetic foot infectionInfections and infestations0/2341/233
Lung infectionInfections and infestations0/2341/233
Fibula fractureInjury, poisoning and procedural complications0/2341/233
Diabetic ketoacidosisMetabolism and nutrition disorders0/2341/233
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2341/233
Vertebrobasilar insufficiencyNervous system disorders0/2341/233
Acute myocardial infarctionCardiac disorders1/2340/233
Most frequent other events
Most frequent other events
EventSitagliptinPlacebo
HypoglycaemiaMetabolism and nutrition disorders65/23452/233
Blood glucose increasedInvestigations16/23413/233
Upper respiratory tract infectionInfections and infestations12/23411/233

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SitagliptinPlaceboTotal
Mean58.6 ± 8.456.7 ± 9.157.6 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlaceboTotal
Female104117221
Male130116246
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Shankar RR, Bao Y, Han P, Hu J, Ma J, Peng Y, Wu F, Xu L, Engel SS, Jia W. Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. J Diabetes Investig. 2017 May;8(3):321-329. doi: 10.1111/jdi.12585. Epub 2016 Dec 9. PubMed 27740719 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in Jun 2014, 23 months.

Results were first posted in Jan 2015, 7 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2012
First posted
May 3, 2012
StartActual
Jul 10, 2012
Primary completionActual
Jun 11, 2014
CompletionActual
Jun 25, 2014
Results first posted
Jan 27, 2015
Last update
Aug 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01590797
Responsible party
Sponsor
First posted
May 3, 2012
Start date
Jul 10, 2012
Primary completion
Jun 11, 2014
Completion
Jun 25, 2014
Results posted
Jan 27, 2015
Last update
Aug 17, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion